CHK1 inhibition synergizes with gemcitabine initially by destabilizing the DNA replication apparatus

Cancer Research

Volumn 75, Issue 17, 2015, Pages 3583-3595

  Koh, Siang Boon ^a   Courtin, Aurélie ^a   Boyce, Richard J ^b   Boyle, Robert G ^b   Richards, Frances M ^a   Jodrell, Duncan I ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Sentinel Oncology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 1; DNA; GEMCITABINE; SINGLE STRANDED DNA; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN P53; TP53 PROTEIN, HUMAN;

ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL FATE; CELL POPULATION; CELL SYNCHRONIZATION; CHEMOSENSITIZATION; CONTROLLED STUDY; DNA DAMAGE; DNA FRAGMENTATION; DNA REPLICATION; DNA SYNTHESIS; ENZYME INHIBITION; GENOTOXICITY; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; MICROTUBULE; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; TERMINAL DISEASE; ANALOGS AND DERIVATIVES; CELL DIVISION; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; MITOSIS; PANCREATIC NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; DEOXYCYTIDINE; DNA DAMAGE; DNA REPLICATION; DRUG SYNERGISM; G2 PHASE; HUMANS; MITOSIS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84942929202     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3347     Document Type: Article

References (37)

1. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009;461:1071-8.
2. Gabrielli B, Brooks K, Pavey S. Defective cell cycle checkpoints as targets for anti-cancer therapies. Front Pharmacol 2012;3:9.
3. Schlegel R, Pardee AB. Caffeine-induced uncoupling of mitosis from the completion of DNA replication in mammalian cells. Science 1986;232: 1264-6.
4. Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7- hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 1996;2:791-7.
5. Zuazua-Villar P, Rodriguez R, Gagou ME, Eyers PA, Meuth M. DNA replication stress in CHK1-depleted tumour cells triggers premature (Sphase) mitosis through inappropriate activation of Aurora kinase B. Cell Death Dis 2014;5:e1253.
6. Montano R, Chung I, Garner KM, Parry D, Eastman A. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther 2012; 11:427-38.
7. Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ, et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 2009;8:45-54.
8. Sorensen CS, Syljuasen RG. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res 2012;40:477-86.
9. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011;17:88-96.
10. MorganMA, Parsels LA, Maybaum J, Lawrence TS. Improving the efficacy of chemoradiation with targeted agents. Cancer Discov 2014;4:280-91.
11. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363: 1049-57.
12. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition ofHedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
13. Parsels LA, Qian Y, Tanska DM, Gross M, Zhao L, Hassan MC, et al. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res 2011;17:3706-15.
14. Del Nagro CJ, Choi J, Xiao Y, Rangell L, Mohan S, Pandita A, et al. Chk1 inhibitioninp53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death. Cell Cycle 2014;13:303-14.
15. Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 2008;132:487-98.
16. On KF, Chen Y, Ma HT, Chow JP, Poon RY. Determinants of mitotic catastrophe on abrogation of the G2 DNA damage checkpoint by UCN-01. Mol Cancer Ther 2011;10:784-94.
17. Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat Cell Biol 2014;16:2-9.
18. Ashley AK, Shrivastav M, Nie J, Amerin C, Troksa K, Glanzer JG, et al. DNAPK phosphorylation of RPA32 Ser4/Ser8 regulates replication stress checkpoint activation, fork restart, homologous recombination and mitotic catastrophe. DNA Repair 2014;21:131-9.
19. Polo SE, Jackson SP. Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev 2011;25:409-33.
20. Shechter D, Costanzo V, Gautier J. ATR and ATM regulate the timing of DNA replication origin firing. Nat Cell Biol 2004;6:648-55.
21. Mankouri HW, Huttner D, Hickson ID. How unfinished business from S-phase affects mitosis and beyond. EMBO J 2013;32:2661-71.
22. Zachos G, Black EJ, Walker M, Scott MT, Vagnarelli P, Earnshaw WC, et al. Chk1 is required for spindle checkpoint function. Dev Cell 2007;12: 247-60.
23. Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, et al. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov 2012;2:524-39.
24. Beeharry N, Rattner JB, Caviston JP, Yen T. Centromere fragmentation is a common mitotic defect of S and G2 checkpoint override. Cell Cycle 2013;12:1588-97.
25. Stevens JB, Abdallah BY, Liu G, Ye CJ, Horne SD, Wang G, et al. Diverse system stresses: common mechanisms of chromosome fragmentation. Cell Death Dis 2011;2:e178.
26. Stevens JB, Abdallah BY, Regan SM, Liu G, Bremer SW, Ye CJ, et al. Comparison of mitotic cell death by chromosome fragmentation to premature chromosome condensation. Mol Cytogenet 2010;3:20.
27. Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, Lawrence TS. Role of checkpoint kinase 1 in preventing prematuremitosis in response to gemcitabine. Cancer Res 2005;65:6835-42.
28. McNeely S, Conti C, Sheikh T, Patel H, Zabludoff S, Pommier Y, et al. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell Cycle 2010;9:995-1004.
29. Matthews DJ, Yakes FM, Chen J, Tadano M, Bornheim L, Clary DO, et al. Pharmacological abrogation of S-phase checkpoint enhances the antitumor activity of gemcitabine in vivo. Cell Cycle 2007;6:104-10.
30. Toledo LI, Altmeyer M, Rask MB, LukasC, Larsen DH, Povlsen LK, et al. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell 2013;155:1088-103.
31. Kubara PM, Kerneis-Golsteyn S, Studeny A, Lanser BB, Meijer L, Golsteyn RM. Human cells enter mitosis with damaged DNA after treatment with pharmacological concentrations of genotoxic agents. Biochem J 2012;446: 373-81.
32. Syljuasen RG, Jensen S, Bartek J, Lukas J. Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases. Cancer Res 2006;66: 10253-7.
33. Montano R, Thompson R, Chung I, Hou H, Khan N, Eastman A. Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK- 8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo. BMC Cancer 2013;13:604.
34. Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol 2015;33: 1060-6.
35. Sausville E, Lorusso P, Carducci M, Carter J, Quinn MF, Malburg L, et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol 2014;73:539-49.
36. Andre N, Carre M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol 2014;11:413-31.
37. Sturgeon CM, Roberge M. G2 checkpoint kinase inhibitors exert their radiosensitizing effects prior to the G2/M transition. Cell Cycle 2007; 6:572-5.